Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technologies. Vivaldiās DeltaFLU universal influenza vaccine is in Phase 2 clinical development. Its Delta-19 universal influenza/Covid-19 vaccine will enter clinical trials in 2021. Delta NS1 is a versatile and robust technology platform for self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain. Delta NS1-based vaccines have the unique ability to rapidly induce interferon, generating protection against circulating viruses entering the nasal passages, and activating systemic antibody and cell-based protective immunity.
View Top Employees from Vivaldi BiosciencesWebsite | http://www.vivaldibiosciences.com |
Revenue | $7 million |
Employees | 10 (8 on RocketReach) |
Founded | 2006 |
Phone | (646) 472-0130 |
Technologies |
JavaScript,
HTML,
Twitter
+10 more
(view full list)
|
Industry | Biotechnology Research, Chemicals, Petrochemicals, Glass & Gases, Biotechnology, Manufacturing, Science and Engineering, Life Science, Medical Device, Health Care |
Web Rank | 29 Million |
Keywords | Vivaldi Biotech |
Competitors | Bellicum Pharmaceuticals, Inc., Etubics, Genecure LLC, GlobeImmune, Inc., Immunomic Therapeutics, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325414 Companies, NAICS Code 325 Companies |
Looking for a particular Vivaldi Biosciences employee's phone or email?
The Vivaldi Biosciences annual revenue was $7 million in 2024.
Bill Wick is the Chief Executive Officer, Director of Vivaldi Biosciences.
8 people are employed at Vivaldi Biosciences.
The NAICS codes for Vivaldi Biosciences are [32, 3254, 32541, 325414, 325].
The SIC codes for Vivaldi Biosciences are [28, 283].